Clinical trial
Dose Escalation Study Combining Oral Capecitabine (Xeloda) and Radiotherapy for…
NCT00216437 · James A. Haley Veterans Administration Hospital, U.S. Fed · Terminated
Key facts
| NCT number | NCT00216437 |
|---|---|
| Title | Dose Escalation Study Combining Oral Capecitabine (Xeloda) and Radiotherapy for Patients With Unresectable Liver or Cholangiocarcinoma |
| Official title | A Phase I Dose Escalation Study to Assess the Maximum Tolerated Dose and Feasibility of Combining Oral Capecitabine (Xeloda) and Conformal Radiotherapy (CRT) for Patients With Unresectable Hepatocellular Carcinoma, Multiple Hepatic Metastases or Cholangiocarcinoma |
| Lead sponsor | James A. Haley Veterans Administration Hospital, U.S. Fed |
| Collaborators | Hoffmann-La Roche Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer of Liver |
| Intervention type | Drug |
| Interventions | Capecitabine (Xeloda) |
| Enrollment | 30 |
| Start date | Dec 1, 2004 |
| Completion | Mar 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | Nov 12, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: